Abstract:BACKGROUND: The RAS/RAF/MEK/ERK and PI3K/AKT/mTOR signaling pathways all belong to mitogen-activated protein kinase (MAPK) signaling pathways, Mutations in any one of the upstream genes (such as the RAS gene or the BRAF gene) may be transmitted to the protein through transcription or translation, resulting in abnormal activation of the signaling pathway. This study investigated the relationship between the KRAS gene mutation and the clinicopathological features and prognosis of colorectal cancer (CRC), and the effect of KRAS mutations on its associated proteins in CRC, with an aim to clarify the cause of tumor progression and drug resistance caused by mutation of the KRAS gene.AIM: To investigate the KRAS gene and RAS pathway signaling molecules in CRC and to analyze their relationship with clinicopathological features and prognosis.METHODS: Colorectal cancer tissue specimens from 196 patients were analyzed for KRAS mutations using quantitative polymerase chain reaction and for KRAS, BRAF, MEK, and ERK protein expression levels using immunohistochemistry of tumor microarrays. To analyze differences of RAS pathway signaling molecule expression levels in different KRAS gene status, the relationships between these parameters and clinicopathological features, 4-year progression-free survival, and overall survival were analyzed by independent sample t test, Kaplan-Meier plots, and the log-rank test. Predictors of overall and disease-free survival were assessed using a Cox proportional hazards model.RESULTS: Of the 196 patients, 62 (32%) carried mutations in codon 12 (53/62) or codon 13 (9/62) in exon 2 of the KRAS gene. KRAS, BRAF, ERK, and MEK protein expression was detected in 71.4%, 78.8%, 64.3%, and 50.8% of CRC tissues, respectively. There were no significant differences between KRAS mutation status and KRAS, BRAF, MEK, or ERK protein levels. Positive expression of KRAS and ERK was associated with poor tumor differentiation, and KRAS expression was also associated with age < 56 years. MEK expression was significantly associated with distant metastasis (P < 0.05). The 4-year progression-free survival rate, but not overall survival rate, was significantly higher in patients with KRAS-negative tumors than in those with KRAS-positive tumors (P < 0.05), whereas BRAF, MEK, and ERK expression was unrelated to survival. Multivariate analysis showed that only the expression of KRAS protein was a risk factor for tumor recurrence (P < 0.05). No other clinicopathological factors correlated with KRAS, BRAF, MEK, or ERK expression.CONCLUSION: KRAS gene mutations do not affect downstream protein expression in CRC. KRAS protein is associated with poor tumor differentiation, older age, and a risk of tumor recurrence.

Progress in Ras Gene and Relationship Between Abnormality of Ras Regulation and Tumor

Epigenetic Silencing of a Ca2+-regulated Ras GTPase-activating Protein RASAL Defines a New Mechanism of Ras Activation in Human Cancers

RASAL1 Expression and Ras Activity with Gastrointestinal Tumors: a Review

The Abnormal Expression of Rb Gene Product in the Hepatocellular Carcinogenesis of Rats and its Significance

Ras superfamily GTPase activating proteins in cancer: Potential therapeutic targets?

The RASAL1 Gene and Tumors

Hypermethylation and clinicopathological significance of RASAL1 gene in gastric cancer.

Targeting RAS mutants in malignancies: successes, failures, and reasons for hope

Expression and Biological Significance of Ras Protein Activator Like-1 Gene in Gastric Cancer Cell Lines

Tumor Suppression of Ras GTPase-Activating Protein RASA5 Through Antagonizing Ras Signaling Perturbation in Carcinomas.

Clinical significance of RASAL1 expression in colorectal carcinoma

Study on Relationship Between RasTG and Pancreatic Carcinoma

Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer

Kras Mutation in Tumorigenesis and Cancer Therapy

Novel Tumor Suppressive Role of the RAS GTPase-Activating Protein RASA5 to RAS Signaling Perturbation in Human Carcinomas

The research progress of the correlation between K-Ras gene and prognosis of metastatic colorectal cancer

Signaling Passway and Related Biological Function Mediated by R-Ras

Development and safety of investigational and approved drugs targeting the RAS function regulation in RAS mutant cancers

High Expression of Ras-related Protein 1A Promotes an Aggressive Phenotype in Colorectal Cancer Via PTEN/FOXO3/CCND1 Pathway.

Research Progress in Ras Association Domain Family 1A Gene Hypermethylation and Cancer

Clinical Study of Expression Levels of RASGRF1 in Colorectal Cancer Tissues